Top Page
Microba Life Sciences Limited
(Sydney:MAP)
Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)
Microba Life Sciences Limited Business Overview & Revenue Model
Microba Life Sciences Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.67M | 15.67M | 12.09M | 5.42M | 4.69M | 3.73M |
| Gross Profit | 7.44M | 7.44M | 5.91M | -6.77M | 2.37M | -5.30M |
| EBITDA | -22.47M | -10.51M | -17.10M | -17.07M | -9.86M | -6.28M |
| Net Income | -14.94M | -14.94M | -19.94M | -12.68M | -11.47M | -7.52M |
Balance Sheet | ||||||
| Total Assets | 47.44M | 47.44M | 58.04M | 46.95M | 39.48M | 18.49M |
| Cash, Cash Equivalents and Short-Term Investments | 11.74M | 11.74M | 20.89M | 32.04M | 30.79M | 13.03M |
| Total Debt | 3.23M | 3.23M | 1.58M | 1.14M | 1.33M | 269.02K |
| Total Liabilities | 14.94M | 14.94M | 16.82M | 8.23M | 5.94M | 3.55M |
| Stockholders Equity | 32.49M | 32.49M | 41.22M | 38.57M | 33.54M | 14.94M |
Cash Flow | ||||||
| Free Cash Flow | -12.34M | -14.91M | -19.95M | -15.43M | -12.32M | -7.85M |
| Operating Cash Flow | -12.01M | -12.01M | -15.57M | -12.39M | -10.45M | -7.18M |
| Investing Cash Flow | -2.83M | -2.83M | -13.95M | -3.00M | -1.73M | -522.48K |
| Financing Cash Flow | 5.58M | 5.58M | 18.39M | 16.68M | 29.22M | 13.84M |
Microba Life Sciences Limited Technical Analysis
Microba Life Sciences Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$58.08M | 30.83 | 98.18% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$169.25M | ― | -111.23% | ― | 12.96% | 40.81% | |
48 Neutral | AU$34.21M | -4.70 | -97.79% | ― | ― | 23.85% | |
41 Neutral | AU$45.67M | -2.25 | -40.54% | ― | 29.60% | 33.00% | |
41 Neutral | AU$60.19M | -2.93 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$49.96M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Microba Life Sciences Limited Corporate Events
Microba Life Sciences Limited has received a $3 million R&D Tax Incentive refund from the Australian Government for its research and development activities in the 2024/2025 financial year. This financial boost strengthens Microba’s cash position and supports its ongoing innovation in gastrointestinal diagnostics and therapeutics, which are pivotal in delivering transformative health outcomes globally.
Microba Life Sciences Limited announced the cessation of Dr. Hyungtae Kim as a director, effective November 19, 2025. Dr. Kim, who was a director nominee of Macrogen, Inc., held 17,828,431 ordinary fully paid shares in the company. This change in directorship may influence the company’s strategic direction and stakeholder relationships, particularly with Macrogen, Inc.
Microba Life Sciences Limited held its Annual General Meeting, where all proposed resolutions were passed, except for the re-election of Dr. Hyungtae Kim, who retired. Notably, the approval of a 10% Placement Facility was achieved, which could enhance the company’s financial flexibility and strategic positioning.
Microba Life Sciences Limited has announced a board renewal process, appointing Mr. Stéphane Chatonsky as an Independent Non-Executive Director to enhance its global commercialization strategy and accelerate the growth of its microbiome testing business. This appointment, effective November 20, 2025, follows the retirement of Non-Executive Directors Mr. Richard Bund and Dr. Hyungtae Kim, who have significantly contributed to the company’s governance and strategic evolution. The board changes aim to strengthen Microba’s position in the industry as it continues to expand its operations globally.
Microba Life Sciences Limited announced its Q1 FY26 Investor Presentation and Webinar, which will be led by CEO Dr. Luke Reid. The company invites investors to engage through its interactive investor platform, where they can register for the webinar, submit questions, and receive updates on the company’s quarterly reports and key announcements. This initiative aims to enhance investor engagement and transparency, potentially strengthening Microba’s market position and stakeholder relations.
Microba Life Sciences Limited reported significant growth in its core testing products for Q1 FY26, with a 145% increase in test volumes compared to the previous corresponding period. The company is on track to meet its regional break-even guidance by the end of FY26, driven by strong sales growth in Australia and the UK. The strategic shift to focus on high-margin growth products has resulted in a 42% revenue increase, excluding legacy products, and a 26% reduction in operating expenditure. Microba’s transition to core growth products is expected to enhance profitability and operational efficiency, supported by a recent capital raise and ongoing cost management initiatives.
Microba Life Sciences Limited announced the release of its Q1 FY26 Quarterly Activities Report and plans to host a Quarterly Investor Webinar on 28 October 2025. The webinar, led by CEO Dr. Luke Reid, will provide insights into the company’s recent activities and future plans, offering stakeholders an opportunity to engage directly with management. This initiative underscores Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.
Microba Life Sciences Limited has announced its 2025 Annual General Meeting (AGM), inviting shareholders to participate either in person or by proxy. The AGM will be held on November 19, 2025, in Brisbane, and shareholders are encouraged to submit questions in advance. The company emphasizes the importance of electronic communication, urging shareholders to update their communication preferences to receive important documents and updates efficiently. This move aligns with Microba’s commitment to enhancing stakeholder engagement and operational transparency.
Microba Life Sciences Limited has announced that its Annual General Meeting (AGM) will take place on November 19, 2025, in Brisbane, Queensland. The meeting will include the re-election of directors, with nominations closing on October 7, 2025. This AGM is a significant event for stakeholders as it will address leadership roles within the company, potentially impacting its strategic direction and market positioning.
Microba Life Sciences Limited announced a change in director’s interest in its securities, with notices lodged outside the required timeframe due to administrative oversight. The company has implemented measures to ensure timely compliance in the future, such as integrating director option expiry dates into its compliance calendar and scheduling regular reviews of equity-related events. This move underscores Microba’s commitment to maintaining its continuous disclosure obligations, which is crucial for its operational transparency and stakeholder trust.
Microba Life Sciences Limited announced a change in the director’s interest notice, with Richard Bund, a director of the company, disposing of 690,290 ordinary shares through SA Microba Holdings Pty Ltd. This transaction was part of the administration of a deceased estate and did not affect Bund’s personal holdings, indicating a procedural adjustment rather than a strategic shift in company operations.
Microba Life Sciences Limited announced a change in the director’s interest, specifically regarding Richard Bund’s holdings. The announcement detailed the lapse of 200,000 options and the on-market disposal of 1,829,460 ordinary shares, resulting in Bund holding 31,651,339 ordinary shares. This change reflects adjustments in the director’s investment portfolio, potentially impacting the company’s stock market activities and shareholder perceptions.